ClinicalTrials.gg
TerminatedNCT05534529Updated Apr 6, 2025

Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

A Phase 1 interventional study of Rezafungin Acetate in Invasive Fungal Infections, sponsored by Mundipharma Research Limited. Terminated at 10 sites in 3 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Mundipharma Research Limited (part of Mundipharma) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study had initially anticipated dosing of the first cohort within 4-9 months of activation; however the study faced significant challenges in recruitment. In order to adhere to the previously approved PIP plan, the study could not be redesigned.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Invasive Fungal Infections with a site in United Kingdom — none open to participants now, none under way, none of them phase 3. Invasive Fungal Infections · United Kingdom.

Started
2023
the only one that year
Phase 1
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
2 of 10
Mundipharma Research Limited

Among the 10 studies in Invasive Fungal Infections with a site in United Kingdom, this one is the only one that started in 2023, is the only one in phase 1, and was the 10th registered.

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

Browse Invasive Fungal Infections studies →

Open to participants now

None of the 10 studies in Invasive Fungal Infections with a site in United Kingdom is open now. The open studies under Invasive Fungal Infections, anywhere →

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Invasive Fungal Infections with a site in United Kingdom as a file.
02

Study summary

This study aimed to learn what levels of rezafungin were in the blood after dosing and how safe it was, in children and adolescents below 18 years old who were already receiving treatment for a fungal infection, a suspected fungal infection or at risk of fungal infection.

The main question the researchers wanted to answer in this trial was:

  • What were the levels of rezafungin in the blood after the participants were dosed? The researchers also wanted to know what medical problems happened during this trial.

The participants in this trial received one dose of rezafungin on day 1 through a needle into a vein, called an intravenous (IV) infusion. The dose of rezafungin was measured in milligrams (mg) and given to the participants according to their body weight in kilograms (mg/kg).

The doctors checked the participants' health and asked questions about what medications they were taking and took blood samples to check the levels of rezafungin in the participants' blood.

After receiving the treatment at day 30, the doctors checked the participants' health.

This was an "open-label" trial. This means each participant knew what they were receiving, and the doctors and trial staff also knew.

Read the detailed description

To date, there are no clinical studies evaluating rezafungin in paediatric subjects.

The primary objective of the trial was to evaluate the pharmacokinetics (PK) of a single intravenous (IV) dose of rezafungin in paediatric participants from birth to \< 18 years, receiving concomitant systemic antifungals as prophylaxis for invasive fungal infection (IFI) or to treat a suspected or confirmed fungal infection.

The secondary objective was to assess the safety and tolerability of a single IV dose of rezafungin in the subjects.

This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at approximately 10 sites across at least 3 countries in Europe.

The study will be conducted in 3 parts:

  • Part 1 will include subjects aged 12 to \<18 years (Group 1)
  • Part 2 will include subjects aged 6 to \<12 years (Group 2), and subjects aged 2 to \<6 years (Group 3).
  • Part 3 will include subjects from birth to \<2 years (Group 4) The study design for the 3 parts is similar and comprises a Screening (pre-treatment) period from Day -3 to Day -1, Dosing on Day 1 (single IV infusion of rezafungin) followed by multiple PK sampling, and a Follow up visit on Day 30 (± 5 days). PK sampling will be performed at specified timepoints for each group.

Limitations and Caveats Due to recruitment challenges, the study was terminated following enrollment of 2 participants aged between 12-17 years in Group 1 (Part 1). Group 2, 3 (Part 2) and Group 4 (Part 3) were not initiated prior to study termination. Due to the low number of participants in this study, baseline characteristics, outcome measure results and adverse events have not been reported to reduce the potential of re-identification.

03

Conditions studied

  • Invasive Fungal Infections

Keywords

  • Rezafungin, children and adolescents, systemic anti-fungal treatment
  • Pharmacokinetics
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female paediatric subjects from birth to \<18 years of age who are receiving concomitant systemic antifungals (oral or IV) as prophylaxis for invasive fungal infection (IFI) or to treat a suspected or confirmed fungal infection.

Exclusion criteria

Exclusion Criteria:

  • History of anaphylaxis, , or any serious reaction to the echinocandin class of antifungals and/or of this formulation
  • Previous or current medical conditions of severe ataxia, persistent tremors, intracranial hemorrhage or neuropathy, or a diagnosis of epilepsy, multiple sclerosis, or a movement disorder
  • Subjects with impaired renal or hepatic functions
  • Subjects with intestinal hypoxia, ischemia, necrosis, or necrotizing enterocolitis
  • Subject status is unstable
  • Subject is unlikely to complete required study procedures
  • Participation in another interventional treatment trial with an agent or presence of an investigational device at the time of or within 28 days preceding the informed consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Rezafungin

    It is IMP.

    Drug: Rezafungin Acetate

Interventions

  • This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.

    Also known as: Rezafungin

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Rezafungin

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: At end-of-infusion ± 15 minutes, then between 3 and 4 hours after start of infusion, between 6 and 8 hours after start of infusion, at 48 hours (± 4 hours) after start of infusion, and at 168 hours (± 12 hours) after start of infusion

  2. Time at which the Cmax of Rezafungin Was Observed (Tmax)

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

  3. Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Rezafungin

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

  4. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Rezafungin

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

  5. Total Clearance (CL) of Rezafungin

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

  6. Volume of Distribution of Rezafungin at Steady-state (Vss)

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

  7. Apparent Volume of Distribution of Rezafungin During the Terminal Phase (Vz)

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

  8. Terminal Elimination Half-life of Rezafungin (t1/2)

    Blood samples of 1 mL each were collected for the analysis of rezafungin plasma concentration. PK parameters were determined from the rezafungin concentration-time data using non-compartmental methods and actual sampling times.

    Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    A TEAE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of rezafungin, whether or not considered related to the rezafungin that was not present prior to the administration of rezafungin or any event present that worsened in either severity or frequency following exposure to rezafungin. Clinically significant changes in laboratory evaluations (including haematology, blood chemistry and urinalysis), vital signs, 12-lead electrocardiogram (ECG) and physical examination findings were also reported as TEAEs.

    Time frame: From start of study on Day 1 to follow up Day 30 (+/- days)

07

Study locations

10 sites
  • Universitätsklinikum Essen Zentrum für Kinder- und Jugendmedizin
    Essen, Germany
  • Universitätsklinikum Frankfurt, Goethe Universität Klinik für Kinder- und Jugendmedizin
    Frankfurt, Germany
  • Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin
    Münster, Germany
  • Hospital Universitario de Burgos
    Burgos, Spain
  • Hospital Universitario 12 de Octubre.
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    London, United Kingdom
  • Saint Mary's Hospital, Imperial College Healthcare NHS Trust
    London, United Kingdom
  • St. George's University Hospitals, NHS Foundation Trust
    London, United Kingdom
  • Southampton General Hospital, University Hospital Southampton NHS Foundation Trust
    Southampton, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in May 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2022
First posted
Sep 9, 2022
StartActual
Sep 13, 2023
Primary completionActual
May 23, 2024
CompletionActual
Oct 14, 2024
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05534529
Responsible party
Sponsor
First posted
Sep 9, 2022
Start date
Sep 13, 2023
Primary completion
May 23, 2024
Completion
Oct 14, 2024
Last update
Apr 6, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Biafungin acetate

Start the discussion